MedPath
Found 2 clinical trials|View Analysis
Sort by:

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

Phase 2
Withdrawn
Conditions
Heart Failure NYHA Class III
Heart Failure NYHA Class II
Heart Failure NYHA Class I
Interventions
Drug: Valsartan 80 mg bid
Drug: Enalapril 10 mg bid
Drug: Sacubitril-Valsartan 200 mg bid
Drug: Icatibant
Drug: Placebo
First Posted Date
2016-12-29
Last Posted Date
2018-01-11
Lead Sponsor
Vanderbilt University Medical Center
Registration Number
NCT03005184
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Phase 3
Terminated
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Drug: LCZ696 200 mg BID
Drug: Enalapril 10 mg BID
First Posted Date
2009-12-18
Last Posted Date
2016-08-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
8442
Registration Number
NCT01035255
Locations
🇻🇪

Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

© Copyright 2025. All Rights Reserved by MedPath